Description

The purpose of this program is to expand access to naloxone and other Food and Drug Administration (FDA) approved overdose reversal medications for emergency treatment of known or suspected opioid overdose. The recipients will collaborate with other prescribers at the community level to implement trainings on policies, procedures, and models of care for prescribing, co-prescribing, and expanding access to naloxone and other FDA-approved overdose reversal medications to the specified population of focus (i.e., rural or urban).

Eligibility

Eligibility is limited to FQHCs (as defined in section 1861(aa) of the Social Security Act), opioid treatment programs as defined under part 8 of title 42, Code of Federal Regulations, and practitioners dispensing narcotic drugs pursuant to section 303(g) of the Controlled Substances Act (including secondary and higher education settings).

Award Information

Funding Mechanism: Cooperative Agreement

Anticipated Total Available Funding: Up to $1,400,000

Anticipated Number of Awards: 7

Anticipated Award Amount: Up to $200,000 per year per award

Length of Project: Up to 5 years

Cost Sharing/Match Required?: No

Proposed budgets cannot exceed $200,000 in total costs (direct and indirect) in any year of the proposed project. Annual continuation awards will depend on the availability of funds, grantee progress in meeting project goals and objectives, timely submission of required data and reports, and compliance with all terms and conditions of award.